Insider Buying: Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Purchases $242,300.76 in Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. purchased 9,906 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were bought at an average price of $24.46 per share, with a total value of $242,300.76. Following the purchase, the insider directly owned 6,324,431 shares in the company, valued at approximately $154,695,582.26. The trade was a 0.16% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, May 11th, Ra Capital Management, L.P. purchased 39,869 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.81 per share, with a total value of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. purchased 1,483 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.98 per share, with a total value of $37,045.34.
• On Wednesday, May 6th, Ra Capital Management, L.P. purchased 68,018 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.60 per share, with a total value of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.63 per share, with a total value of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The shares were bought at an average price of $18.00 per share, with a total value of $48,150,000.00.

Hemab Therapeutics Price Performance

Shares of NASDAQ COAG opened at $28.56 on Thursday. Hemab Therapeutics Holdings, Inc. has a twelve month low of $23.00 and a twelve month high of $36.61.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.